5.12
간접 작용 콜린 작용제는 시냅스 틈에서 아세틸콜린에스테라제 효소와 상호 작용하여 아세틸콜린이 콜린과 아세테이트로 분해되는 것을 방지하는 약제입니다. 결과적으로 시냅스 틈의 아세틸콜린 농도가 증가합니다. 이러한 작용제는 작용 기간에 따라 가역적 억제제와 비가역적 억제제로…
간접 작용성 콜린성 작용제는 시냅스 틈새에서 AChE 효소에 결합하여 ACh 가수분해를 억제합니다. 그 결과 시냅스에서 ACh의 농도가 증가하여 간접적으로 콜린성 작용이 향상됩니다.
일반적으로 작용 기간에 따라 가역적 또는 비가역적 억제제로 분류됩니다.
가역적 억제제는 단작용 및 중간작용제입니다.
속효성제는 에드로포늄과 같은 4차 암모늄기를 함유하는 단순 알코올입니다.
중간작용제에는 네오스티그민(neostigmine) 및 피소스티그민(physostigmine)과 같은 탄수화물 에스테르가 포함됩니다.
네오스티그민(Neostigmine)은 4차 암모늄기(quaternary ammonium group)를 지닌 카바메이트(carbamate)이고, 피소스티그민(physostigmine)은 3차 아민기(tertiary amine group)를 가진 자연 발생 카바메이트(carbamate)입니다.
비가역적 억제제에는 유기인산염이 포함됩니다. 그들은 여러 치환체를 가진 인산 유도체이며, 치환기 중 하나는 불안정한 그룹으로 기능합니다.
예를 들어, 에코티오페이트는 2개의 알콕시기와 1개의 티오콜린기로 구성됩니다. 신경 가스인 사린은 알콕시 1개, 알킬 1개, 할로겐 1개를 가지고 있습니다. 여기서 티오콜린과 할로겐은 불안정한 그룹입니다.
View the full transcript and gain access to JoVE Core videos
Q1: How do indirect-acting cholinergic agonists increase acetylcholine levels at the synapse?
Indirect-acting cholinergic agonists bind to acetylcholinesterase (AChE) enzymes at the synaptic cleft and inhibit the breakdown of acetylcholine into choline and acetate. By preventing ACh hydrolysis, these agents allow acetylcholine to accumulate in the synapse, indirectly enhancing cholinergic neurotransmission without directly activating cholinergic receptors.
Q2: What is the difference between reversible and irreversible cholinesterase inhibitors?
Reversible inhibitors are short- and intermediate-acting agents that temporarily bind to acetylcholinesterase, allowing enzyme recovery. Irreversible inhibitors, such as organophosphates, permanently inactivate the enzyme through covalent bonding. Reversible agents like neostigmine and physostigmine have predictable durations of action, while irreversible inhibitors produce prolonged effects.
Q3: What structural features distinguish short-acting reversible cholinesterase inhibitors?
Short-acting reversible inhibitors are simple alcohols bearing quaternary ammonium groups, exemplified by edrophonium. The quaternary ammonium moiety provides positive charge, enhancing binding to the negatively charged active site of acetylcholinesterase. This structural feature enables rapid, reversible enzyme inhibition with brief duration of action.
Q4: How do intermediate-acting agents like neostigmine and physostigmine differ structurally?
Both neostigmine and physostigmine are carbamic esters, but they differ in amine groups and origin. Neostigmine is a synthetic carbamate with a quaternary ammonium group, while physostigmine is a naturally occurring carbamate containing a tertiary amine group. These structural differences affect their pharmacokinetic properties and tissue penetration.
Q5: What makes organophosphates irreversible cholinesterase inhibitors?
Organophosphates are phosphoric acid derivatives containing multiple substituents, including a labile group that forms a covalent bond with acetylcholinesterase. Echothiophate contains two alkoxy groups and a thiocholine labile group, while sarin contains an alkoxy group, alkyl group, and halogen labile group. This covalent modification permanently inactivates the enzyme.
Q6: Why are quaternary ammonium groups important in cholinesterase inhibitor design?
Quaternary ammonium groups provide permanent positive charge, enabling strong electrostatic interactions with the negatively charged active site of acetylcholinesterase. This structural feature enhances binding affinity and specificity for the enzyme. Agents like edrophonium and neostigmine utilize quaternary ammonium moieties to achieve potent cholinesterase inhibition.
Q7: How do the labile groups in organophosphates contribute to their irreversible action?
Labile groups in organophosphates, such as the thiocholine in echothiophate or the halogen in sarin, are readily displaced during enzyme binding. This displacement allows the phosphorus atom to form a stable covalent bond with a serine residue in the acetylcholinesterase active site. The resulting phosphorylated enzyme cannot hydrolyze acetylcholine, producing irreversible inhibition.